Sang Pil Lee

Title: Innovations of Sang Pil Lee

Introduction

Sang Pil Lee is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of immunotherapy through his innovative research and development. With a total of 2 patents, his work focuses on advancing medical treatments for various disorders.

Latest Patents

One of his latest patents is titled "Monoclonal antibody specifically binding to LAG-3 and use thereof." This invention involves a monoclonal antibody that binds to lymphocyte-activation gene 3 (LAG-3), which includes a heavy chain variable region and a light chain variable region. The antibody is designed to inhibit the activity of LAG-3, making it a promising candidate for the development of immunotherapeutic agents for disorders associated with this gene.

Another significant patent is "Antibody against human DLK1 and use thereof." This invention relates to an antibody against delta-like 1 homolog (DLK1) or an antigen-binding fragment thereof. It includes a nucleic acid encoding the antibody, a vector comprising the nucleic acid, and a method for producing the antibody. This patent also covers an antibody drug conjugate (ADC) for cancer treatment, a pharmaceutical composition for treating cancer, and a composition for diagnosing cancer.

Career Highlights

Sang Pil Lee is currently employed at Y-Biologics Inc., where he continues to push the boundaries of medical research. His work has the potential to lead to groundbreaking treatments in the field of oncology and immunotherapy.

Collaborations

He collaborates with talented individuals such as Ji-Young Shin and Sunha Yoon, contributing to a dynamic research environment that fosters innovation.

Conclusion

Sang Pil Lee's contributions to the field of immunotherapy through his patents and collaborations highlight his role as a significant inventor. His work is paving the way for new treatments that could benefit many patients in the future.